Last week our board attended the ASCPT 2023 meeting, which took place in person again for the first time since 2019! It was a very inspiring meeting with many interesting talks and posters. We specifically want to highlight one. During one of the sessions dr Jing Yang of Pfizer WRDM Clinical Pharmacology presented a poster that argued that in some situations it would be very advantageous to perform first-in-human studies in healthy subjects before going to oncology patients, particularly in the case of molecularly targeted agents and immuno-oncological compounds. This is exactly in line with CHDR’s vision and current strategy, which is aimed at applying our extensive battery of ex vivo and in vivo tools to demonstrate target engagement in early clinical pharmacology studies in healthy subjects in the oncology field.
Take a look at our fact sheet or reach out to our team at oncology@chdr.nl to learn more about early phase oncology trials at CHDR. You can also see a snapshot of dr Yang’s findings below (made with the explicit consent of dr Yang). Looking forward to collaborating with Pfizer!
